Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents

Eur J Med Chem. 2010 Sep;45(9):4096-103. doi: 10.1016/j.ejmech.2010.05.070. Epub 2010 Jun 9.

Abstract

By modifying the chemical structure of anti-orthopoxvirus compound ST-246, we designed and synthesized a series of tricyclononene carboxamide derivatives and tested their anti-HIV-1 activity and cytotoxicity. We found that benzoimidazol-containing compound 7g was highly effective in inhibiting HIV-1 R5 infection with an IC(50) value of 0.41 microM and a selectivity index of 292, but it exhibited no significant inhibitory activity on HIV-1 reverse transcriptase, integrase and protease. CoMFA was used to analyze structure-activity relationships with good predictive power (r(2) = 0.921; q(2) = 0.582). Moreover, the CoMFA model showed that the length of the molecule, the amide, and the amine moieties all played crucial roles in anti-HIV activity. These results suggest that 7g may serve as a lead for the development of novel anti-HIV-1 therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / chemical synthesis
  • Anti-HIV Agents / chemistry*
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / toxicity
  • Cell Line
  • Drug Discovery
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • Heterocyclic Compounds, 4 or More Rings / chemical synthesis
  • Heterocyclic Compounds, 4 or More Rings / chemistry*
  • Heterocyclic Compounds, 4 or More Rings / pharmacology*
  • Heterocyclic Compounds, 4 or More Rings / toxicity
  • Inhibitory Concentration 50
  • Models, Molecular
  • Molecular Conformation

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 4 or More Rings